AIM Vaccine Co., Ltd. announced that on March 2, 2024, the randomized, blinded and comparable vaccine-controlled Phase II clinical trial of the Group's tetravalent meningococcal conjugate vaccine (MCV4) was officially initiated, with the Yunnan Provincial Center for Disease Control and Prevention as the responsible institution, and the Center for Disease Control and Prevention of Longyang District, Baoshan and the Center for Disease Control and Prevention of Weishan Yi and Hui Autonomous County, Dali Prefecture as the research sites. Epidemic cerebrospinal meningitis (hereinafter referred to as meningococcal disease) is a bacterial vaccine-preventable acute infectious disease caused by Neisseria meningitidis, with meningitis and sepsis as the clinical manifestations. The disease is widely distributed, has an acute onset, rapid progression, high infectivity, high latent infection rate and high mortality rate, and could cause serious harm.

In the World Health Organization's grading of vaccine-preventable diseases, meningococcal series products are at a high priority level. The Group ' s MCV4 can prevent epidemic cerebrospinal meningitis caused by Group A, C, Y and W135 Neisseria meningitidis, and other invasive diseases.